KEFTAB Drug Patent Profile
✉ Email this page to a colleague
When do Keftab patents expire, and what generic alternatives are available?
Keftab is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in KEFTAB is cephalexin hydrochloride. There are twenty-nine drug master file entries for this compound. Additional details are available on the cephalexin hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for KEFTAB?
- What are the global sales for KEFTAB?
- What is Average Wholesale Price for KEFTAB?
Summary for KEFTAB
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 68 |
| Clinical Trials: | 1 |
| Patent Applications: | 187 |
| DailyMed Link: | KEFTAB at DailyMed |
Recent Clinical Trials for KEFTAB
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Merck Sharp & Dohme Corp. | Phase 1 |
US Patents and Regulatory Information for KEFTAB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | KEFTAB | cephalexin hydrochloride | TABLET;ORAL | 050614-001 | Oct 29, 1987 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Lilly | KEFTAB | cephalexin hydrochloride | TABLET;ORAL | 050614-003 | May 16, 1988 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Lilly | KEFTAB | cephalexin hydrochloride | TABLET;ORAL | 050614-002 | Oct 29, 1987 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
